Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.61 |
| ▸ | HTR3B | O95264 | 1/20 | 0.61 |
| ▸ | HTR3A | P46098 | 1/20 | 0.61 |
| ▸ | BACE1 | P56817 | 1/20 | 0.61 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.61 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.61 |
| ▸ | F10 | P00742 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 4/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
| ▸ | KLK1 | P06870 | 1/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.51 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29409142 | 1.00 | TDP1 (0.70) | TDP1HTR3EHTR3BHTR3ABACE1 | |
| Hydrochloric Acid SCHEMBL5204720 | 0.98 | TDP1 (0.68) | TDP1HTR3EHTR3BHTR3ABACE1 | |
| Hydrochloric Acid SCHEMBL31164757 | 0.98 | TDP1 (0.68) | TDP1HTR3EHTR3BHTR3ABACE1 | |
| SCHEMBL1974375 | 0.86 | RAD52 (0.67) | TDP1HTR3EHTR3BHTR3ABACE1 | |
| SCHEMBL4151145 | 0.86 | TDP1 (0.51) | TDP1HTR3EHTR3BHTR3ABACE1 | |
| Hydrochloric Acid SCHEMBL4148629 | 0.84 | TDP1 (0.50) | TDP1HTR3EHTR3BHTR3ABACE1 | |
| Hydrochloric Acid SCHEMBL5204712 | 0.84 | TDP1 (0.50) | TDP1HTR3EHTR3BHTR3ABACE1 | |
| Hydrochloric Acid SCHEMBL30012925 | 0.84 | TDP1 (0.50) | TDP1HTR3EHTR3BHTR3ABACE1 | |
| SCHEMBL656416 | 0.84 | TDP1 (0.72) | TDP1HTR3EHTR3BHTR3ABACE1 | |
| SCHEMBL30040705 | 0.84 | TDP1 (0.72) | TDP1HTR3EHTR3BHTR3ABACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4237413-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022094244-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2022-05-05 | — | — | WO | disclosed |
| EP-3962906-A1 | SUBSTITUTED CYCLOALKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3027615-B1 | ANTI-INFECTIVE COMPOUNDS | PASTEUR INSTITUT KOREA (KR) | 2021-07-21 | — | — | EP | disclosed |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | UNIVERSITY OF WASHINGTON (US) | 2021-02-09 | — | — | US | disclosed |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | UNIVERSITY OF WASHINGTON (US) | 2021-02-09 | — | — | US | disclosed |
| WO-2020223538-A1 | SUBSTITUTED CYCLOALKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2020-11-05 | — | — | WO | disclosed |
| US-20200347043-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-05 | — | — | US | disclosed |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON | 2017-09-28 | — | — | US | disclosed |
| US-7625919-B2 | 4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090281325-A1 | METHOD FOR SELECTIVELY PRODUCING PRIMARY AMINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1961733-A1 | METHOD FOR SELECTIVELY PRODUCING PRIMARY AMINE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-08-27 | — | — | EP | disclosed |
| EP-1135374-B9 | BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1135374-B1 | BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2003035615-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| US-6528653-B2 | E.g., 4,6-dihydro 4-(heterocyclic ring-methylene)thieno(2,3-b) pyrrolidin-5-one derivatives; tumor necrosis factor ) inhibitors; anticarcinogenic, -proliferative and -arthritic agents; Alzheimer's disease; cardiovascular disorders | HOFFMANN-LA ROCHE, INC. | 2003-03-04 | — | — | US | disclosed |
| EP-1135374-A1 | BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6204282-B1 | TREATING CANCER, RETINOPATHY, ATHEROSCLEROSIS, VASCULAR RESTENOSIS, OR OSTEOPOROSIS. | SCHERING CORPORATION | 2001-03-20 | — | — | US | disclosed |
| WO-2000032578-A1 | BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347043-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | TDP1 2482/4885HTR3E 2896/4885HTR3B 1905/4885 |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | AARS1, MTR, GARS1 | TDP1 415/4885HTR3E 2492/4885HTR3B 2528/4885 |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | TDP1 2235/4885HTR3E 2154/4885HTR3B 1301/4885 |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | AARS1, MTR, GARS1 | TDP1 415/4885HTR3E 2492/4885HTR3B 2528/4885 |
| US-20090281325-A1 | METHOD FOR SELECTIVELY PRODUCING PRIMARY AMINE COMPOUND | NAT1, AADAC, AOC3 | TDP1 3599/4885HTR3E 161/4885HTR3B 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.